Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06939999 in Advanced Solid Tumors
NCT03854227Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Mar 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-06939999 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal cancer and 3 more (6 arms), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities at 29 days, Treatment-Emergent Adverse Events at 15 months and 2 more. Started Mar 2019; status: terminated.
02
Drugs
PF-06939999
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)esophageal cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03854227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854227.